Rituximab Treatment for Adult Patients with Focal Segmental Glomerulosclerosis
نویسندگان
چکیده
منابع مشابه
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.
BACKGROUND AND OBJECTIVES Isolated case reports have shown a beneficial effect of rituximab on pediatric patients with primary FSGS, but there is no information about rituximab treatment of FSGS in adults. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS All patients who had biopsy-proven FSGS and were treated with rituximab in Spain were identified, independent of their positive or negative res...
متن کاملRituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Treatment of nephrotic syndrome due to minimal change disease and focal segmental glomerulosclerosis remains a challenge since steroid dependence, steroid resistance and a relapsing disease course exhibits a high cumulative steroid dosage. The necessity of using alternative steroid-sparing immunosuppressive agents with potential toxic side effects also restricts their long-term use. Rituximab, ...
متن کاملSuccessful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab
Collapsing focal segmental glomerulosclerosis (FSGS), or collapsing glomerulopathy (CG), responds poorly to commonly employed therapies, with a high proportion of patients progressing to end-stage renal disease. We report an adult in a nephrotic state, diagnosed with minimal-change disease on biopsy, who failed to respond to steroids, calcineurin inhibitors (CNIs), mycophenolate mofetil and cyc...
متن کاملRituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to end-stage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sph...
متن کاملFocal segmental glomerulosclerosis--does treatment work?
This study also confirms that the mean time to remission in treated FSGS patients can be as long as 5 months and that treatment should continue beyond that time. It reports a relapse rate of 20% and a spontaneous remission rate of 30.7%. Recent studies have also demonstrated higher spontaneous remission rates than those previously [7] , particularly in comparison with American series. The highe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2012
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.51.6854